Status: Recruiting
A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.
Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.
Participants needed: 64
Trial details
Phase: Phase 1Age: 30-89Biological sex: AllType: InterventionalSponsor: Longevity Biotech Australia Pty Ltd (subsidiary)Updated: Aug 21, 2026Locations: 2
Eligibility criteria
Male or female, 30-89 years inclusive at screening [+3]
Immunomodulators / steroids - HV: any (incl. OTC) within 90 days; PD: systemic w... [+10]